You will generally need to get a referral letter from your NHS GP, Private GP, or other doctor to access this service or treatment. Find out more including how we can assist you
Ocrelizumab (Ocrevus) Subcutaneous Injection
Ocrelizumab, known under the brand name Ocrevus, is a disease-modifying therapy that targets specific immune cells involved in MS progression. Scientific advancements have led to a revolutionary new medium of delivering this treatment via a jab, which takes just minutes compared to previous infusions that could last multiple hours.
02036532045
What is a Ocrelizumab (Ocrevus) Subcutaneous Injection?
Thousands of people with multiple sclerosis (MS) in England are set to benefit from this new, faster treatment option.
Previously, ocrelizumab was administered via intravenous (IV) infusions, which could take up to four hours. The new injection significantly reduces treatment time, allowing patients to spend less time in hospitals. With a shorter treatment time, more new patients can access the revolutionary Ocrevus jab and begin their treatment journey.
Ocrelizumab is a disease-modifying therapy that targets specific immune cells involved in MS progression. Clinical trials have shown it to be highly effective in halting the symptoms of MS. In fact, 97% of patients in trials experienced no relapses or new brain lesions over 48 weeks.
The Ocrelizumab injection is expected to not only improve the quality of life for MS patients but also reduce the burden on healthcare resources. It could free up hospital capacity and allow clinicians to focus on other patients.
This new treatment option is particularly beneficial for patients with difficult-to-access veins, who may have previously faced challenges with IV infusions of Ocrevus, as the jab only needs to enter below the skin's surface.
Why might you need Ocrevus?
You may need Ocrevus if you have:
- Relapsing multiple sclerosis (RMS)
- Primary progressive multiple sclerosis (PPMS)
What to expect on the day of your appointment
Your appointment will typically involve the following steps:
- Diagnosis of MS: This includes neurological scans and clinical assessment.
- Pre-medication: You'll take pre-medication (usually antihistamines and anti-inflammatory drugs) about 30 minutes before the infusion.
- Subcutaneous infusion: The Ocrevus injection takes approximately 10 minutes.
- Observation: You'll be monitored for 60 minutes after the Ocrevus infusion.
- Follow-up: You'll have a follow-up clinical review with your treating neurologist.
Risks associated with Ocrevus
Potential risks associated with Ocrevus include:
- Injection-related responses: Rash, itching, redness
- Slight suppression of the immune system: Increased risk of infections (e.g., colds, viruses)
Why choose OneWelbeck for Ocrevus?
- Highly experienced clinical team: Our team has extensive expertise in treating MS and administering Ocrevus.
- Convenient location in Central London: We're easily accessible for patients in the London area.
- Easy access to cross-specialty referrals: If needed, we can connect you with other specialists for comprehensive care.
- Exclusive subcutaneous delivery: We're one of the few facilities in the UK offering the new subcutaneous method of Ocrevus delivery, which is less time-consuming and more efficient than the traditional IV infusion.
Treatment Costs
£14,000
Book a consultation
Nov 2024
MON TUE WED THU FRI SAT SUN
Currently selected day
Available consultations
Treatment Programme
Ocrelizumab (Ocrevus) Subcutaneous Injection
Introduction
Treatment
1-2 hrs, Home same day
Preparation
Pre-medication taken 30 mins before
Risks
Rash, itching, redness
Aftercare
60 min observation, Follow up review with Neurol...
Price
14000
Doctor Referral Only
Self-Pay Available
This treatment is available for self-paying users. If you would like to see more information on pricing visit our pricing and payments page.
Consultation Required
For this treatment you will need to have a 1-to-1 consultation at OneWelbeck first. To book in with our team of expert clinicians or to find out more about the process contact the relevant centre team.